All In Biotech

Free tool

FAERS Monitor: Oseni

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 022426 or its brand name (Oseni, Alogliptin Benzoate, Pioglitazone Hydrochloride). Reports on generic versions are filed under their own applications.

Reports

249

Serious

67

27% of reports

Hospitalization

36

Death reported

4

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • weight increased21
  • drug ineffective11
  • fatigue11
  • rash11
  • blood glucose increased10
  • pancreatitis10
  • headache9
  • vision blurred9
  • arthralgia8
  • myalgia8
  • nausea8
  • abdominal pain upper7
  • pain7
  • joint swelling6
  • oedema6

Reports by year received

View as table
YearReports
20133
201463
2015103
201632
201713
20189
20197
20206
20215
20221
20242
20254
20261

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,910 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
pancreatitisSignal1016.08.7126
oedemaSignal69.34.237
weight increasedSignal217.95.3121
vision blurredSignal95.52.929
blood glucose increasedSignal104.52.424
joint swellingSignal64.21.912
myalgiaSignal84.02.015
abdominal pain upperSignal72.91.47
rashSignal112.11.26
arthralgia81.60.81
headache91.20.60
fatigue111.20.70
pain71.00.50
nausea80.90.40
drug ineffective110.70.41

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.